home > news > detailed info

Nemera reinforces its value proposition with a refreshing visual identity


More modern, our new brand identity truly embodies who we are, how we partner with our customers and ultimately the value we bring to millions of patients across the world through our drug delivery device solutions.

At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience. We are passionately growing our business around the combination product value chain through our holistic offering. We partner with our customers in an agile manner to accelerate bringing their products to patients. As our business evolves, we are pleased to introduce our new visual identity that reflects this transformation.

“We are thrilled to launch our new identity that re-unites our purpose of putting patients first and our commitment of being a holistic and agile partner. Together, they tell the unique story of our heritage and where we are headed alongside our customers in the drug delivery devices industry.” says Marc Hämel, Nemera’s CEO

Different look. Same commitment.

Our website. A user-friendly, easy to navigate and content rich website that not only tells our story but also helps understand how we support our customers with our products, services and capabilities. It also makes it easier to contact and work with us. Live the experience at and our social media channels! Our logo. Warm, friendly and forward looking, our logo speaks to our open, inclusive and patient-centric ethos.

phone +33 4 74 94 06 54
email 20 avenue de la Gare, 38290 – La Verpillière, France
Print this page
Send to a friend
News and Press Releases

Clinical Researcher of the Year - The Americas 2021 winners announced

The winners of the 2021 Clinical Researcher of the Years – The Americas competition have been announced, with the exceptional talent of clinical researchers across the Americas recognised during a live virtual awards ceremony.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement